Limbix

Limbix is a prescription digital therapeutic company focused on developing mental health treatments for adolescents. The company's flagship product is SparkRx, a self-guided cognitive behavioral therapy (CBT) app designed for teenagers and young adults aged 13 to 22 with symptoms of depression. SparkRx teaches skills such as mood tracking, behavioral activation, problem-solving, and mindfulness. While not FDA-cleared or approved, SparkRx was made available under the FDA's Covid-19 emergency guidance for digital health devices treating psychiatric disorders.

Limbix developed SparkRx using its proprietary Limbix Synapse platform, which enables the efficient building, distribution, and commercialization of secure and compliant digital therapeutics. The platform allows for customizable content across mobile and tablet devices, integration with health system partners, and the ability to run remote clinical trials. In August 2022, Limbix launched the Synapse platform publicly to expand its pipeline of digital therapeutics.

The company has conducted several clinical studies to evaluate SparkRx's efficacy. In 2021, Limbix was awarded a USD 3.6 million grant from the National Institute of Mental Health to conduct a double-blind, sham-controlled, randomized trial of SparkRx in partnership with the Duke Clinical Research Institute. Limbix aims to address the growing adolescent mental health crisis by providing an accessible digital treatment option, particularly for teens who face long wait times to see mental health professionals.

In July 2023, Limbix was acquired by Big Health, a provider of digital therapeutics for adult mental health conditions. The acquisition added SparkRx to Big Health's portfolio of products, which includes Sleepio for insomnia and Daylight for anxiety in adults.

Key customers and partnerships

Limbix has partnered with the Duke Clinical Research Institute to conduct clinical trials of SparkRx. The company also collaborated with Children's Hospital Los Angeles, where Dr. Jeffrey I. Gold, Limbix's former Chief Clinical Officer, held several leadership positions.

Limbix's products are designed to be prescribed by licensed healthcare professionals to adolescent patients with symptoms of depression in the US.